Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS

Minoda,Masaya; Kawamoto,Teruya; Ueha,Takeshi; Kamata,Etsuko; Morishita,Masayuki; Harada,Risa; Toda,Mitsunori; Onishi,Yasuo; Hara,Hitomi; Kurosaka,Masahiro; Akisue,Toshihiro

doi:10.3892/ijo.2015.3077

Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS

Authors:
- Masaya Minoda
- Teruya Kawamoto
- Takeshi Ueha
- Etsuko Kamata
- Masayuki Morishita
- Risa Harada
- Mitsunori Toda
- Yasuo Onishi
- Hitomi Hara
- Masahiro Kurosaka
- Toshihiro Akisue
View Affiliations

Affiliations: Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Chuo-ku, Kobe 650-0017, Japan, Division of Rehabilitation Medicine, Kobe University Graduate School of Medicine, Chuo-ku, Kobe 650-0017, Japan
Published online on: July 9, 2015 https://doi.org/10.3892/ijo.2015.3077
Pages: 891-899
Copyright: © Minoda et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Survivin is a member of the inhibitor of apoptosis family, which is known to inhibit mitochondrial apoptosis. Survivin is highly expressed in cancers and plays an important role in cancer cell survival, and increased survivin expression is an unfavorable prognostic marker in cancer patients. YM155, a novel small-molecule survivin suppressant, selectively suppresses survivin expression, resulting in the induction of apoptosis in various malignancies. However, the roles of survivin in human malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma (MFH/UPS) have not been studied. In the present study, we examined survivin expression in human musculoskeletal tumor tissues, and the effect of survivin inhibition by siRNA or YM155 on apoptotic activity in human MFH/UPS cell lines. In tumor tissues, mRNA expression of survivin was significantly higher in MFH/UPS samples than in benign schwannomas. Moreover, in vitro studies revealed that both survivin siRNA and YM155 suppressed survivin expression and inhibited MFH/UPS cell proliferation in a dose- and a time-dependent manner. Further, the numbers of apoptotic cells significantly increased with YM155 treatment. in vivo, tumor volume in YM155-treated groups was significantly reduced without significant bodyweight loss. Increased apoptotic activity along with decreased survivin expression was also observed in YM155-treated tumors. The findings in this study strongly suggest that survivin suppressants, including YM155, contribute to the suppression of human MFH/UPS cell growth via promoting mitochondrial apoptosis, and that survivin may be a potent therapeutic target for the novel treatment of human MFH/UPS.

View Figures

View References

1	Spira AI and Ettinger DS: The use of chemotherapy in soft-tissue sarcomas. Oncologist. 7:348–359. 2002. View Article : Google Scholar : PubMed/NCBI
2	Matushansky I, Charytonowicz E, Mills J, Siddiqi S, Hricik T and Cordon-Cardo C: MFH classification: Differentiating undifferentiated pleomorphic sarcoma in the 21st Century. Expert Rev Anticancer Ther. 9:1135–1144. 2009. View Article : Google Scholar : PubMed/NCBI
3	Le Doussal V, Coindre JM, Leroux A, Hacene K, Terrier P, Bui NB, Bonichon F, Collin F, Mandard AM and Contesso G: Prognostic factors for patients with localized primary malignant fibrous histiocytoma: A multicenter study of 216 patients with multivariate analysis. Cancer. 77:1823–1830. 1996. View Article : Google Scholar : PubMed/NCBI
4	Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M, et al: Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci. 102:614–621. 2011. View Article : Google Scholar : PubMed/NCBI
5	Ren YQ, Zhang HY, Su T, Wang XH and Zhang L: Clinical significance of serum survivin in patients with pancreatic ductal adenocarcinoma. Eur Rev Med Pharmacol Sci. 18:3063–3068. 2014.PubMed/NCBI
6	Caldas H, Holloway MP, Hall BM, Qualman SJ and Altura RA: Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo. J Med Genet. 43:119–128. 2006. View Article : Google Scholar
7	Vischioni B, van der Valk P, Span SW, Kruyt FA, Rodriguez JA and Giaccone G: Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. Ann Oncol. 15:1654–1660. 2004. View Article : Google Scholar : PubMed/NCBI
8	Mobahat M, Narendran A and Riabowol K: Survivin as a preferential target for cancer therapy. Int J Mol Sci. 15:2494–2516. 2014. View Article : Google Scholar : PubMed/NCBI
9	Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008. View Article : Google Scholar
10	Pennati M, Folini M and Zaffaroni N: Targeting survivin in cancer therapy: Fulfilled promises and open questions. Carcinogenesis. 28:1133–1139. 2007. View Article : Google Scholar : PubMed/NCBI
11	Span PN, Sweep FC, Wiegerinck ET, Tjan-Heijnen VC, Manders P, Beex LV and de Kok JB: Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem. 50:1986–1993. 2004. View Article : Google Scholar : PubMed/NCBI
12	Trieb K, Lehner R, Stulnig T, Sulzbacher I and Shroyer KR: Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol. 29:379–382. 2003. View Article : Google Scholar : PubMed/NCBI
13	Wu YF, Liang XJ, Liu YY, Gong W, Liu JX, Wang XP, Zhuang ZQ, Guo Y and Shen HY: +Antisense oligonucleotide targeting survivin inhibits growth by inducing apoptosis in human osteosarcoma cells MG-63. Neoplasma. 57:501–506. 2010. View Article : Google Scholar : PubMed/NCBI
14	Liang X, Da M, Zhuang Z, Wu W, Wu Z, Wu Y and Shen H: Effects of Survivin on cell proliferation and apoptosis in MG-63 cells in vitro. Cell Biol Int. 33:119–124. 2009. View Article : Google Scholar
15	Lechler P, Renkawitz T, Campean V, Balakrishnan S, Tingart M, Grifka J and Schaumburger J: The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro. BMC Cancer. 11:1202011. View Article : Google Scholar : PubMed/NCBI
16	Taubert H, Kappler M, Bache M, Bartel F, Köhler T, Lautenschläger C, Blümke K, Würl P, Schmidt H, Meye A, et al: Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients. Oncogene. 24:5258–5261. 2005. View Article : Google Scholar : PubMed/NCBI
17	Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I, Matsuhisa A, et al: YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 67:8014–8021. 2007. View Article : Google Scholar : PubMed/NCBI
18	Kelly RJ, Thomas A, Rajan A, Chun G, Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, et al: A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 24:2601–2606. 2013. View Article : Google Scholar : PubMed/NCBI
19	Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y, et al: Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res. 15:3872–3880. 2009. View Article : Google Scholar : PubMed/NCBI
20	Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT, Shamsili S and Papadopoulos KP: A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer. 118:3128–3134. 2012. View Article : Google Scholar
21	Kiyozuka Y, Nakagawa H, Uemura Y, Senzaki H, Yamamoto A, Noguchi T, Mizuta H, Nakanishi K, Nakano S and Tsubura A: Novel cell lines established from a human myxoid malignant fibrous histiocytoma arising in the uterus. Cancer Genet Cytogenet. 127:7–15. 2001. View Article : Google Scholar : PubMed/NCBI
22	Nakatani T, Marui T, Yamamoto T, Kurosaka M, Akisue T and Matsumoto K: Establishment and characterization of cell line TNMY1 derived from human malignant fibrous histiocytoma. Pathol Int. 51:595–602. 2001. View Article : Google Scholar : PubMed/NCBI
23	Okada Y, Akisue T, Hara H, Kishimoto K, Kawamoto T, Imabori M, Kishimoto S, Fukase N, Onishi Y and Kurosaka M: The effect of bevacizumab on tumour growth of malignant fibrous histiocytoma in an animal model. Anticancer Res. 30:3391–3395. 2010.PubMed/NCBI
24	Radaelli S, Stacchiotti S, Casali PG and Gronchi A: Emerging therapies for adult soft tissue sarcoma. Expert Rev Anticancer Ther. 14:689–704. 2014. View Article : Google Scholar : PubMed/NCBI
25	Ranieri G, Mammì M, Donato Di Paola E, Russo E, Gallelli L, Citraro R, Gadaleta CD, Marech I, Ammendola M and De Sarro G: Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: A new treatment for metastatic soft tissue sarcoma. Crit Rev Oncol Hematol. 89:322–329. 2014. View Article : Google Scholar
26	Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, et al: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 13:1537–1545. 1995.PubMed/NCBI
27	Sanna MG, da Silva Correia J, Ducrey O, Lee J, Nomoto K, Schrantz N, Deveraux QL and Ulevitch RJ: IAP suppression of apoptosis involves distinct mechanisms: The TAK1/JNK1 signaling cascade and caspase inhibition. Mol Cell Biol. 22:1754–1766. 2002. View Article : Google Scholar : PubMed/NCBI
28	Mita AC, Mita MM, Nawrocki ST and Giles FJ: Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 14:5000–5005. 2008. View Article : Google Scholar : PubMed/NCBI
29	Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
30	Nachmias B, Ashhab Y and Ben-Yehuda D: The inhibitor of apoptosis protein family (IAPs): An emerging therapeutic target in cancer. Semin Cancer Biol. 14:231–243. 2004. View Article : Google Scholar : PubMed/NCBI
31	Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003. View Article : Google Scholar : PubMed/NCBI
32	Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 22:8581–8589. 2003. View Article : Google Scholar : PubMed/NCBI
33	Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M and Altieri DC: Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 351:882–883. 1998. View Article : Google Scholar : PubMed/NCBI
34	Lin CY, Hung HC, Kuo RC, Chiang CP and Kuo MY: Survivin expression predicts poorer prognosis in patients with areca quid chewing-related oral squamous cell carcinoma in Taiwan. Oral Oncol. 41:645–654. 2005. View Article : Google Scholar : PubMed/NCBI
35	Reed JC: The Survivin saga goes in vivo. J Clin Invest. 108:965–969. 2001. View Article : Google Scholar : PubMed/NCBI
36	Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, et al: An IAP-IAP complex inhibits apoptosis. J Biol Chem. 279:34087–34090. 2004. View Article : Google Scholar : PubMed/NCBI
37	Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I and Reed JC: HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 22:2729–2740. 2003. View Article : Google Scholar : PubMed/NCBI
38	Fukuda S and Pelus LM: Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 5:1087–1098. 2006. View Article : Google Scholar : PubMed/NCBI
39	Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F and Daidone MG: Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci. 59:1406–1412. 2002. View Article : Google Scholar : PubMed/NCBI
40	Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M, Montagna L, Piccoli P, Chilosi M and Caligaris-Cappio F: Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood. 97:2777–2783. 2001. View Article : Google Scholar : PubMed/NCBI
41	Rödel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R and Rödel C: Survivin as a radio-resistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res. 65:4881–4887. 2005. View Article : Google Scholar
42	Kappler M, Köhler T, Kampf C, Diestelkötter P, Würl P, Schmitz M, Bartel F, Lautenschläger C, Rieber EP, Schmidt H, et al: Increased survivin transcript levels: An independent negative predictor of survival in soft tissue sarcoma patients. Int J Cancer. 95:360–363. 2001. View Article : Google Scholar : PubMed/NCBI
43	Tsuji N, Asanuma K, Kobayashi D, Yagihashi A and Watanabe N: Introduction of a survivin gene-specific small inhibitory RNA inhibits growth of pancreatic cancer cells. Anticancer Res. 25B:3967–3972. 2005.
44	Wang F, Bai HR, Wang J, Bai YZ and Dou CW: Glioma growth inhibition in vitro and in vivo by single chain variable fragments of the transferrin receptor conjugated to survivin small interfering RNA. J Int Med Res. 39:1701–1712. 2011. View Article : Google Scholar : PubMed/NCBI
45	Wang J-W, Liu Y, Tian H and Zhang W: Effect of survivin-siRNA on drug sensitivity of osteosarcoma cell line MG-63. Chin J Cancer Res. 22:68–72. 2010. View Article : Google Scholar
46	Zaffaroni N, Pennati M and Daidone MG: Survivin as a target for new anticancer interventions. J Cell Mol Med. 9:360–372. 2005. View Article : Google Scholar : PubMed/NCBI
47	Ling X, Bernacki RJ, Brattain mg and Li F: Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem. 279:15196–15203. 2004. View Article : Google Scholar : PubMed/NCBI
48	Faversani A, Vaira V, Moro GP, Tosi D, Lopergolo A, Schultz DC, Rivadeneira D, Altieri DC and Bosari S: Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors. Breast Cancer Res. 16:R552014. View Article : Google Scholar : PubMed/NCBI
49	Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T, Keating A and de Bono JS: A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol. 23:968–973. 2012. View Article : Google Scholar